Radius Health To Announce Third Quarter 2017 Financial Results, Host Conference Call And Live Webcast On November 2, 2017

WALTHAM, Mass., Oct. 09, 2017 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that it will release its third quarter 2017 financial results on Thursday, November 2, 2017. The Company will host a conference call and live audio webcast at 4:30 p.m. ET that day to discuss the results and provide a company update.

Conference Call Information:
Date: Thursday, November 2, 2017
Time: 4:30 p.m. ET
Domestic Dial-in Number: (866) 323-7965
International Dial-in Number: (346) 406-0961
Conference ID: 96777747
Live webcast: https://edge.media-server.com/m6/p/5c3izimp

A replay of the conference call/webcast will be available from November 2, 2017 at 7:30 p.m. ET until November 9, 2017 at 6:30 p.m. ET. To access the replay, dial (855) 859-2056 for U.S. or (404) 537-3406 for International. The replay conference ID is 96777747.

The live audio webcast of the call can be accessed from the Investors section of the Company's website, www.radiuspharm.com. A webcast replay will be also available for 14 days. The full text of the announcement and financial results will also be available on the Company's website.

About Radius
Radius is a science-driven fully integrated biopharmaceutical company developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius' lead product, TYMLOS™ (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Radius' Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe. Radius’ clinical pipeline includes an investigational abaloparatide transdermal patch for potential use in osteoporosis; the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women; and, RAD140, a non-steroidal, selective androgen receptor modulator (SARM), under investigation for potential use in hormone receptor positive breast cancer. For more information, please visit www.radiuspharm.com.

Investor / Media Relations Contact:
Alex Fudukidis
Tel: (646) 942-5632
Email: alex.fudukidis@russopartnersllc.com

Back to news